Introduction
Breast cancer is the most common malignant disease among women in both developing and
developed countries1. As of 2018, breast cancer accounts for 24% of new cancer cases and
15% of cancer deaths globally2. According to the 2011-2015 cancer registry conducted in
Bangkok, Thailand, breast cancer is also the most prevalent cancer, comprising 29.4% of all
cancer cases3. According to Virani et al., age-standardized incidence rate of breast cancer in
2012 in Thailand stands at 26.2 per 100,000 people4. Breast cancer is linked with westernized
lifestyle and economic development3. As such, breast cancer incidence is projected to increase
both globally and in the Asia-Pacific region. Global breast cancer incidence is increasing at a
steady rate of 0.5% whilst incidence within the Asia-Pacific region is reporting an annual
increase of 3-4%5.
Statistics have shown that between 1985 and 2015, survival in metastatic breast cancer has
significantly improved with HER2 positive subset showing the most notable differences. The
HER2 positive subtype improved survival resulted from the availability of transtuzumab and new
cytotoxic agents6. Although breast cancer treatment is improving dramatically within the last few
decades, breast cancer screening is lagging behind. Breast cancer screening, namely
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for thisthis version posted November 29, 2021. ; https://doi.org/10.1101/2021.11.29.21266992doi: medRxiv preprint
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
mammography, has been recommended for decades7, and still is the main breast cancer
screening modality as of 20198. Breast Imaging-Reporting and Data System score (BI-RADS
score), established in 1995 and completed with ultrasonography interpretation in 2003, was set
up as a quality assurance to homogenize the collected data by mammography and
ultrasonography reports. BI-RADS score is still in use in most countries as of today9.
Current recommendations from the National Comprehensive Cancer Network (NCCN),
published in 2018, differentiates breast cancer screening modality into 3 groups: basic, core and
enhanced resources. Basic resources, aiming to improve-specific outcomes, recommend
clinical encounters without the need for breast imaging. Core resources, providing major
improvements in disease outcome without financial prohibition, recommend the use of
ultrasonography alone. As for enhanced resources, the NCCN recommends diagnostic
mammography with the use of screening mammography in high-risk cases10. The following
recommendation by NCCN is in accordance with the American Cancer Society 2015 guideline
for breast cancer, which recommends regular screening mammography at age 45 years in an
average risk woman. Women between the age of 45 and 54 should be screened annually, whilst
women 55 years and older should continue screening annually or transition to biennial
screening11. However in women of Asian descent, a concern has been raised about accuracy of
breast cancer detection as a result of high breast density as opposed to Western women4. In the
status quo, guidelines and research publications within East Asian countries have suggested
contradictory action. A retrospective study in women with breast cancer rural China concluded
that detection of breast cancer using ultrasonography is more sensitive than mammography in
women with high-density breasts, thus recommending ultrasonography for breast cancer
screening12. On the other hand, the Japanese Breast Cancer Society Clinical Practice
Guidelines of 2018 advises against using ultrasonography as an adjunct to breast cancer
screening in the general population as there are currently no studies that have shown that the
following intervention will reduce the breast cancer mortality rate13. Moreover, Okonkwo et al.
showed that the cost-effectiveness of clinical breast examination in India compares favorably
with the use of mammography in Western countries14.
Evidence suggests that Northeast Asian nations have incorporated recommendations from
multiple randomized controlled trials into their clinical guideline. However, this is not the case
with Thailand and other Southeast Asian nations. Research within Thailand reveals that the
cost-effectiveness for once-in-a-lifetime breast cancer screening using mammography accounts
for over 1.8 million Thai baht (approximately 57,000 US dollar using an exchange rate of 31.281
Baht per US dollar, exchange rate taken from Bank of Thailand on 1st April 2021) per 1 year of
quality-adjusted life year (QALY) in women between the ages of 40 and 4915. Thailand’s gross
domestic product (GDP) per capita in fiscal year 2020 was 7,806.7 US dollars, referencing the
data from the World Bank. As reflected from the following data, the cost of population-based
breast cancer screening using mammography in Thailand is unjustifiable comparatively to the
QALY gained by such screening examination, such mass screening, will adds a significant
burden to the government financial status. To the best of our knowledge, there is currently no
research conducted in Thailand or other Southeast Asian nations that investigates the
difference between breast cancer detected by mammography alone versus mammography with
ultrasonography. We identified the discordance between current breast cancer screening
practice in Thailand and the lack of evidence supporting such practice. On 24th March 2021, we
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for thisthis version posted November 29, 2021. ; https://doi.org/10.1101/2021.11.29.21266992doi: medRxiv preprint
performed a routine breast cancer screening event in Thai women using both mammography
and ultrasonography. Within the span of 2 weeks since the opportunistic breast cancer
screening event, we aim to explore the incidence of breast cancer characterized by Breast
Imaging-Reporting and Data System score (BI-RADS score) sorted by age group and breast
composition in middle-aged Thai women using adjunct ultrasonography with mammography and
concordance rates between the two modalities. We hypothesize that additional ultrasonography
might provide better detection rates for breasts with higher BI-RADS score.
Discussion
Current clinical practice for breast cancer screening in King Chulalongkorn Memorial
Hospital, Bangkok, Thailand are as follows: for women under 40 years old ultrasonography is
used with mammography as an adjunct investigation and for women 40 years old and older
mammography is used as the main investigation with ultrasonography as an additional
investigation. This current practice was adopted from international recommendations without
domestic randomized controlled trials to guide actual clinical practice and monitor the
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for thisthis version posted November 29, 2021. ; https://doi.org/10.1101/2021.11.29.21266992doi: medRxiv preprint
effectiveness of the intervention. We question this protocol, as breasts in younger women are
correlated with higher breast density, while the inverse relationship holds true with age16.
Evidence suggests that dense breasts are strongly associated with increased risk of breast
cancer in both premenopausal and postmenopausal women17. There should therefore be a
corresponding difference to how clinicians approach patients of different breast densities. We
suspect that the difference between sensitivity of mammography and ultrasonography stems
from differences in breast density rather than age itself. If notable differences are found within
different breast densities, it would be advisable for suspected breast cancer patients with dense
breasts to suspend the screening examination with mammography and follow up using
ultrasonography exclusively, which might improve the cost-effectiveness of nationwide breast
cancer screening.
The present study examined the BI-RADS score distribution of middle-aged and elderly
Bangkok women, their breast density characteristics, and benefits of adding ultrasound on top
of mammogram based on each breast density classification.
As none of our 49 samples presented with BIRAD 4 or 5, we can conclude that there is a
very low incidence of suspicious breast abnormalities or malignancy (BI-RADS 4 and 5)
detected by mammogram plus ultrasound in randomized middle-aged and older Bangkok
women. On the other hand, all of our 49 participants had negative to probably benign findings
(BIRAD 1-3). Our result is in accordance with research conducted in the United States, stating
that mammography screening for breast cancer yields a detection rate of 3.91 cancer per a
thousand examinations18. As this our study is based on 49 participants, a larger sample size is
needed to confirm the exact incidence of breast cancer in Thai women.
A study concluded that Chinese and Japanese women’s breasts are occupied by dense
tissue 20% higher than Caucasian women’s breasts19. From our study, we found that the most
common breast density in middle-aged and older Thai females is heterogeneous fibroglandular
density. Participants with heterogeneous dense breast and extremely dense breast combined
accounts for just over 20%. We further split the participants into 2 groups by age: from 30-39
years old and 40-60 years old according to current clinical practice. As we categorized
participants in each age group by breast density, we found out that within 7 subjects who are
currently less than 40 years old, 6 participants (85.71%) have heterogeneous fibroglandular
breast and a single participant (14.29%) with extremely dense breast. For 42 participants within
the age group of 40 years old and above, 4 participants (9.52%) have homogeneous dense
breasts while the other 38 subjects (90.48%) have heterogeneously dense breasts. Based on
this cross-sectional study, we therefore found that younger participants are more likely to
present with extremely dense breasts, while presence of heterogeneous dense breasts are
higher in older age group. However, a comparison between Thai women’s breast density and
breast density of women of other nationalities can’t be made from our current study alone.
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for thisthis version posted November 29, 2021. ; https://doi.org/10.1101/2021.11.29.21266992doi: medRxiv preprint
Women with extremely dense breasts present with a 60% BI-RADS score discordance
between mammogram alone and mammogram with adjunct ultrasonography. Comparatively,
only 50% of subjects with heterogeneous dense breasts and 34.21% of subjects with
heterogeneous fibroglandular breasts present such discordance. Our study suggests that
women with higher breast density are more likely to be assigned a higher BI-RADS score with
adjunct ultrasonography. As such, women with higher breast density are more likely to benefit
from the increased sensitivity of higher BI-RADS score which may prompt further necessary
investigations or treatments. We recommend differentiating the clinical practice of breast cancer
screening between initial screening and the follow-up visits. For the first visit, all women should
be screened using both mammography and ultrasonography to ensure the highest detection
rate of breast cancer and determine their breast densities. As for follow-up visits, women should
be screened according to their breast densities. Women with extremely dense breasts should
undergo ultrasonography only and women with heterogeneously dense breasts should be
screened with mammography without adjunct ultrasonography. If this practice is implemented,
we can hope for increased cost-effectiveness of breast cancer screening in Thailand.
Successful nationwide breast cancer screening comprises 3 main pillars: incidence of breast
cancer detected, cost-effectiveness of the screening test and decreased nationwide mortality
rate. According to a Thai research published in 2014, breast cancer incidence accounts for 25.6
cases within a population of 100,00013. From this figure, screening of breast cancer in
asymptomatic Thai general population will yield a very low detection rate. Resulting in the
financial need of over 1 million Thai baht for 1 year of quality-adjusted life year (QALY). This
represents a very low cost-effectiveness using the current screening procedure. To our
knowledge, there is no randomized controlled trial which evaluates the correlation between
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for thisthis version posted November 29, 2021. ; https://doi.org/10.1101/2021.11.29.21266992doi: medRxiv preprint
breast cancer mortality and adjusting breast cancer screening as we proposed. We strongly
encourage that a randomized controlled trial be conducted which may change the standard of
breast cancer screening practice in Thailand.
References
1. Zaidi, Z., & Dib, H. A. (2019). The worldwide female breast cancer incidence and
survival, 2018.
2. Heer, E., Harper, A., Escandor, N., Sung, H., McCormack, V., & Fidler-Benaoudia,
M. M. (2020). Global burden and trends in premenopausal and postmenopausal breast
cancer: A population-based study. The Lancet Global Health, 8(8). doi:10.1016/s2214-
109x(20)30215-1
3. Sangrajrang, S., Laversanne, M., Bausom, R., Mery, L., & Bray, F. (2020). Cancer
incidence and cancer control in Bangkok, Thailand: Results from the cancer registry
2011-15 and projections to 2035. Cancer epidemiology, 67, 101765.
https://doi.org/10.1016/j.canep.2020.101765
4. Virani, S., Bilheem, S., Chansaard, W., Chitapanarux, I., Daoprasert, K., Khuanchana,
S., Leklob, A., Pongnikorn, D., Rozek, L. S., Siriarechakul, S., Suwanrungruang, K.,
Tassanasunthornwong, S., Vatanasapt, P., & Sriplung, H. (2017). National and
Subnational Population-Based Incidence of Cancer in Thailand: Assessing Cancers with
the Highest Burdens. Cancers, 9(8), 108. https://doi.org/10.3390/cancers9080108
5. GREEN, M., & RAINA, V. (2008). Epidemiology, screening and diagnosis of breast
cancer in the Asia-Pacific region: Current perspectives and important considerations.
Asia-Pacific Journal of Clinical Oncology, 4. doi:10.1111/j.1743-7563.2008.00191.x
6. Sundquist, M., Brudin, L., & Tejler, G. (2017). Improved survival in metastatic
breast cancer 1985–2016. The Breast, 31, 46-50. doi:10.1016/j.breast.2016.10.005
7. ADAIR, F. E. (1933). Clinical manifestations of early cancer of the breast. New England
Journal of Medicine, 208(24), 1250-1255. doi:10.1056/nejm193306152082404
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for thisthis version posted November 29, 2021. ; https://doi.org/10.1101/2021.11.29.21266992doi: medRxiv preprint
8. Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram-Baptiste, D.,
Saslow, D., & Wender, R. C. (2019). Cancer screening in the United States, 2019:
A review of current American Cancer Society guidelines and current issues in cancer
screening. CA: A Cancer Journal for Clinicians, 69(3), 184-210. doi:10.3322/caac.21557
9. Balleyguier, C., Ayadi, S., Van Nguyen, K., Vanel, D., Dromain, C., & Sigal, R. (2007).
BIRADS classification in mammography. European journal of radiology, 61(2), 192–194.
https://doi.org/10.1016/j.ejrad.2006.08.033
10. Bevers TB, Helvie M, Bonaccio E, Calhoun KE, Daly MB, Farrar WB, et al. Breast
Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in
Oncology [Internet]. JNCCN. Harborside Press, LLC; 2018 [cited 2021Mar30]. Available
from: https://jnccn.org/view/journals/jnccn/16/11/article-p1362.xml
11. Oeffinger, K. C., Fontham, E. T., Etzioni, R., Herzig, A., Michaelson, J. S., Shih, Y. T., . .
. Wender, R. (2015). Breast cancer screening for women at average risk. JAMA,
314(15), 1599. doi:10.1001/jama.2015.12783
12. Wang, F. L., Chen, F., Yin, H., Xu, N., Wu, X. X., Ma, J. J., Gao, S., Tang, J. H., & Lu, C.
(2013). Effects of age, breast density and volume on breast cancer diagnosis: a
retrospective comparison of sensitivity of mammography and ultrasonography in China's
rural areas. Asian Pacific journal of cancer prevention : APJCP, 14(4), 2277–2282.
https://doi.org/10.7314/apjcp.2013.14.4.2277
13. Uematsu, T., Nakashima, K., Kikuchi, M., Kubota, K., Suzuki, A., Nakano, S., . . . Iwata,
H. (2019). The Japanese breast Cancer Society clinical practice guidelines for breast
cancer screening and Diagnosis, 2018 EDITION. Breast Cancer, 27(1), 17-24.
doi:10.1007/s12282-019-01025-7
14. Okonkwo, Q. L., Draisma, G., Der Kinderen, A., Brown, M. L., & De Koning, H. J.
(2008). Breast cancer screening policies in developing countries: A Cost-effectiveness
analysis for India. JNCI: Journal of the National Cancer Institute, 100(18), 1290-1300.
doi:10.1093/jnci/djn292
15. Anothaisintawee, T., Tantai, N., & Teerawattananon, Y. (2013). Cost–utility of once-in-a-
lifetime breast cancer screening with mammography in Thai women. Journal of Health
Systems Research, 7, 413-420.
16. Checka, C. M., Chun, J. E., Schnabel, F. R., Lee, J., & Toth, H. (2012). The relationship
of mammographic density and age: implications for breast cancer screening. AJR.
American journal of roentgenology, 198(3), W292–W295.
https://doi.org/10.2214/AJR.10.6049
17. Kim, E. Y., Chang, Y., Ahn, J., Yun, J., Park, Y. L., Park, C. H., . . . Ryu, S. (2020).
Mammographic breast density, its changes, and breast cancer risk in premenopausal
and postmenopausal women. Cancer, 126(21), 4687-4696. doi:10.1002/cncr.33138
18. Jiang, Y., Miglioretti, D. L., Metz, C. E., & Schmidt, R. A. (2007). Breast cancer
detection rate: Designing imaging trials to demonstrate improvements. Radiology,
243(2), 360-367. doi:10.1148/radiol.2432060253
19. Maskarinec, G., Meng, L., & Ursin, G. (2001). Ethnic differences in mammographic
densities. International Journal of Epidemiology, 30(5), 959-965.
doi:10.1093/ije/30.5.959
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for thisthis version posted November 29, 2021. ; https://doi.org/10.1101/2021.11.29.21266992doi: medRxiv preprint